
    
      Besides the main objective, there are 3 other objectives as follows.

      To determine dose-limiting toxicity (DLT) Of Oraxol. To characterize the pharmacokinetics of
      HM30181A(pgp inhibitor), paclitaxel and its metabolites following oral administration of
      Oraxol.

      To evaluate anticancer activity of Oraxol.
    
  